What's new? Log in Free sign up

NanoViricides (NNVC)

Company Profile

Company profile

Ticker

NNVC

Exchange

Website

www.nanoviricides.com

CEO

Dr. Anil R. Diwan Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

BOND LABORATORIES, INC.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

760674577

NNVC stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Quarterly report

14 Feb 25

Submission of Matters to a Vote of Security Holders

Quarterly report

14 Nov 24

Definitive proxy

15 Oct 24

27 Sep 24

Departure of Directors or Certain Officers

Prospectus supplement for primary offering

Quarterly report

14 May 24

Entry into a Material Definitive Agreement

Prospectus supplement for primary offering

Latest ownership filings

View all

Fournier, PLLC Stephenson

CVI Investments, Inc.

Altium Capital Management LP

Empery Asset Management, LP

SABBY MANAGEMENT, LLC

Altium Capital Management LP

CVI Investments, Inc.

Makarand Jawadakar

Financial summary

Financial statements Chart NNVC financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 24	Jun 23	Jun 22	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	3.96 mm	3.96 mm	3.96 mm	3.96 mm	3.96 mm	3.96 mm
Cash burn (monthly)	(no burn)	107.28 k	686.35 k	793.89 k	730.32 k	684.22 k
Cash used (since last report)	n/a	221.43 k	1.42 mm	1.64 mm	1.51 mm	1.41 mm
Cash remaining	n/a	3.74 mm	2.54 mm	2.32 mm	2.45 mm	2.55 mm
Runway (months of cash)	n/a	34.8	3.7	2.9	3.4	3.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

NNVC institutional ownership history Ownership history

10.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	36	34	+5.9%
Opened positions	6	6	–
Closed positions	4	6	-33.3%
Increased positions	5	6	-16.7%
Reduced positions	5	5	–

13F shares	Current	Prev Q	Change
Total value	1.97 bn	1.98 bn	-0.4%
Total shares	1.46 mm	1.34 mm	+8.7%
Total puts	500.00	13.00 k	-96.2%
Total calls	29.60 k	21.20 k	+39.6%
Total put/call ratio	0.0	0.6	-97.2%

Largest owners	Shares	Value	Change
Vanguard	510.42 k	$729.90 mm	0.0%
BlackRock	158.75 k	$227.02 mm	0.0%
Compagnie Lombard Odier SCmA	150.00 k	$214.50 mm	0.0%
Renaissance Technologies	145.70 k	$208.35 mm	+26.8%
Geode Capital Management	143.31 k	$205.01 mm	+28.7%
Virtu Financial	63.64 k	$91.00 k	NEW
Bridgeway Capital Management	44.04 k	$62.98 mm	0.0%
STT State Street	41.91 k	$59.93 mm	0.0%
Integrated Wealth Concepts	38.03 k	$54.39 mm	-28.7%
RY Royal Bank of Canada	30.54 k	$44.00 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Virtu Financial	63.64 k	+63.64 k	NEW
Geode Capital Management	143.31 k	+31.96 k	+28.7%
Renaissance Technologies	145.70 k	+30.80 k	+26.8%
Integrated Wealth Concepts	38.03 k	-15.30 k	-28.7%
Dimensional Fund Advisors	0.00	-11.92 k	EXIT
Group One Trading	11.40 k	+11.40 k	NEW
BankPlus Trust Department	7.00 k	+7.00 k	NEW
NBC Securities	6.00	-6.07 k	-99.9%
Susquehanna International	22.25 k	+4.02 k	+22.0%
UBS UBS	4.80 k	+2.11 k	+78.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

'LDH Reports First U.S. H5N1-Related Human Death' - Louisiana Department Of Health

https://ldh.la.gov/news/H5N1-death#:~:text=The%20Louisiana%20Department%20of%20Health,to%20have%20underlying%20medical%20conditions.

NanoViricides Claims NV-387 Could Be Key in Fighting Bird Flu Pandemic

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would

Press releases

From Benzinga Pro

NanoViricides, Inc. Has Filed its Quarterly Report

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / February 19, 2025 / NanoViricides, Inc. (NYSE:NNVC) (the

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

SHELTON, CT / ACCESS Newswire / January 29, 2025 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape,

NanoViricides Engages CRO for Phase II Clinical Trial

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.